Patents by Inventor Alain Fournier

Alain Fournier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200399391
    Abstract: Provided herein are antibodies that specifically bind human CD38, formulations and unit dosage forms comprising the antibodies, methods of preparing the antibodies and methods of using the antibodies.
    Type: Application
    Filed: June 9, 2020
    Publication date: December 24, 2020
    Inventors: Marielle CHIRON BLONDEL, Cendrine LEMOINE, Angela VIRONE-ODDOS, Béatrice CAMERON, Jacques DUMAS, Alain FOURNIER, Jonathan KINGSBURY, Brian MURRAY, Nathan OSTBERG, Sanket PATKE, Zichuan ZHANG
  • Patent number: 9340575
    Abstract: Novel urotensin II receptor (UT) agonists and antagonists are described herein. More specifically, novel derivatives of urotensin II-related peptide (URP) are described herein.
    Type: Grant
    Filed: May 3, 2012
    Date of Patent: May 17, 2016
    Assignee: INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: David Chatenet, Alain Fournier, Myriam Letourneau
  • Publication number: 20150246145
    Abstract: The present invention relates to an adrenomedullin derivative including an adrenomedullin peptide, or a fragment thereof chelated or otherwise bound to at least one active agent. Examples of active agents include a paramagnetic element, a radioactive element and a fibrinolytic agent, among others. Paramagnetic agents have a distribution that is relatively easily shown through Magnetic Resonance Imaging (MRI). Radioactive agents have applications in imaging and delivery of radiations, depending on the specific element included in the active agent. Delivery of fibrinolytic agents mainly to a specific organ, such as for example to the lungs, allows to substantially improve the specificity and efficacy of thrombolytic therapy by allowing local delivery of the fibrinolytic agent, thereby reducing the risks of major bleeding in the therapy of the organ. If the organ is the lungs, a non-limiting example of pathology treatable with the fibrinolytic agent is pulmonary embolus.
    Type: Application
    Filed: May 19, 2015
    Publication date: September 3, 2015
    Inventors: Jocelyn Dupuis, Alain Fournier
  • Patent number: 9062123
    Abstract: The present invention relates to an adrenomedullin derivative including an adrenomedullin peptide, or a fragment thereof chelated or otherwise bound to at least one active agent. Examples of active agents include a paramagnetic element, a radioactive element and a fibrinolytic agent, among others. Paramagnetic agents have a distribution that is relatively easily shown through Magnetic Resonance Imaging (MRI). Radioactive agents have applications in imaging and delivery of radiations, depending on the specific element included in the active agent. Delivery of fibrinolytic agents mainly to a specific organ, such as for example to the lungs, allows to substantially improve the specificity and efficacy of thrombolytic therapy by allowing local delivery of the fibrinolytic agent, thereby reducing the risks of major bleeding in the therapy of the organ. If the organ is the lungs, a non-limiting example of pathology treatable with the fibrinolytic agent is pulmonary embolus.
    Type: Grant
    Filed: July 7, 2011
    Date of Patent: June 23, 2015
    Assignee: PLUMOSCIENCE INC.
    Inventors: Jocelyn Dupuis, Alain Fournier
  • Publication number: 20140113872
    Abstract: Novel urotensin ll receptor (UT) agonists and antagonists are described herein. More specifically, novel derivatives of urotensin ll-related peptide (URP) are described herein.
    Type: Application
    Filed: May 3, 2012
    Publication date: April 24, 2014
    Applicant: INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: David Chatenet, Alain Fournier, Myriam Letourneau
  • Patent number: 8703098
    Abstract: The present invention relates to an adrenomedullin derivative including an adrenomedullin peptide chelated with at least one active agent. Examples of active agents include a paramagnetic element, a radioactive element and a fibrinolytic agent, among others. Paramagnetic agents have a distribution that is relatively easily shown through Magnetic Resonance Imaging (MRI). Radioactive agents have applications in imaging and delivery of radiations, depending on the specific element included in the active agent. Delivery of fibrinolytic agents mainly to a specific organ, such us for example to the lungs, allows to substantially improve the specificity and efficacy of thrombolytic therapy by allowing local delivery of the fibrinolytic agent, thereby reducing the risks of major bleeding in the therapy of the organ. If the organ is the lungs, a non-limiting example of pathology treatable with the fibrinolytic is pulmonary embolus.
    Type: Grant
    Filed: May 24, 2005
    Date of Patent: April 22, 2014
    Assignee: Institut de Cardiologie de Montreal
    Inventors: Jocelyn Dupuis, Alain Fournier
  • Patent number: 8672780
    Abstract: A batting tee with two spaced apart support arms extending upwardly from the base plate, two spaced apart retaining members extending between the support arms and connected thereto or to the base plate, and a pivot extending between the support arms at a location intermediate that of the two retaining members. The shaft's bottom end is received between the two support arms and between the two retaining members and is connected adjacent the bottom end to the two support arms by the pivot extending therethrough. The pivot defining a single pivot axis about which the shaft is pivotable relative to the base plate between a first position in contact with only one of the retaining members and a second position in contact with only the other of the retaining members, for impact energy absorption.
    Type: Grant
    Filed: June 7, 2011
    Date of Patent: March 18, 2014
    Inventor: Alain Fournier
  • Patent number: 8646092
    Abstract: The invention concerns a method for protecting the data of an application compiled in intermediate for execution executed on a digital apparatus equipped with a virtual machine managing the execution of the code via a execution stack defining at least one stack frame corresponding to a method called during the execution of the code. A secured execution mode of the code involves the determination of at least one global checksum associated with each stack frame and, each time that a datum of the code is manipulated, the calculation of a local checksum associated with that datum. The calculation is on one hand, on the global checksum associated with the stack frame corresponding to the manipulated datum and, on the other hand, on at least one part of the other data constituting the stack frame.
    Type: Grant
    Filed: July 18, 2007
    Date of Patent: February 4, 2014
    Assignee: Gemalto SA
    Inventors: Benoit Gonzalvo, Jacques Jean-Alain Fournier
  • Patent number: 8475764
    Abstract: The present invention relates to an adrenomedullin derivative including an adrenomedullin peptide, or a fragment thereof chelated or otherwise bound to at least one active agent. Examples of active agents include a paramagnetic element, a radioactive element and a fibrinolytic agent, among others. Paramagnetic agents have a distribution that is relatively easily shown through Magnetic Resonance Imaging (MRI). Radioactive agents have applications in imaging and delivery of radiations, depending on the specific element included in the active agent. Delivery of fibrinolytic agents mainly to a specific organ, such as for example to the lungs, allows to substantially improve the specificity and efficacy of thrombolytic therapy by allowing local delivery of the fibrinolytic agent, thereby reducing the risks of major bleeding in the therapy of the organ. If the organ is the lungs, a non-limiting example of pathology treatable with the fibrinolytic agent is pulmonary embolus.
    Type: Grant
    Filed: May 12, 2008
    Date of Patent: July 2, 2013
    Assignee: Institut de Cardiologie de Montreal
    Inventors: Jocelyn Dupuis, Alain Fournier
  • Patent number: 8273548
    Abstract: The present invention relates to novel compounds and their uses, in particular their pharmaceutical or diagnostic uses or their use as pharmacological targets. More particularly, the present invention relates to a novel protein, referred to as PAP1, as well as to novel peptides and compounds which are capable of modulating, at least partially, the activity of parkin.
    Type: Grant
    Filed: March 28, 2006
    Date of Patent: September 25, 2012
    Assignee: Aventis Pharma S.A.
    Inventors: Han Koutnikova, Alexis Brice, Alain Fournier, Laurent Pradier, Catherine Prades, Isabelle Arnould-Reguigne, Marie-Françoise Rosier-Montus, Olga Corti
  • Publication number: 20120082619
    Abstract: The present invention relates to an adrenomedullin derivative including an adrenomedullin peptide, or a fragment thereof chelated or otherwise bound to at least one active agent. Examples of active agents include a paramagnetic element, a radioactive element and a fibrinolytic agent, among others. Paramagnetic agents have a distribution that is relatively easily shown through Magnetic Resonance Imaging (MRI). Radioactive agents have applications in imaging and delivery of radiations, depending on the specific element included in the active agent. Delivery of fibrinolytic agents mainly to a specific organ, such as for example to the lungs, allows to substantially improve the specificity and efficacy of thrombolytic therapy by allowing local delivery of the fibrinolytic agent, thereby reducing the risks of major bleeding in the therapy of the organ. If the organ is the lungs, a non-limiting example of pathology treatable with the fibrinolytic agent is pulmonary embolus.
    Type: Application
    Filed: July 7, 2011
    Publication date: April 5, 2012
    Inventors: Jocelyn Dupuis, Alain Fournier
  • Publication number: 20120040780
    Abstract: A batting tee with two spaced apart support arms extending upwardly from the base plate, two spaced apart retaining members extending between the support arms and connected thereto or to the base plate, and a pivot extending between the support arms at a location intermediate that of the two retaining members. The shaft's bottom end is received between the two support arms and between the two retaining members and is connected adjacent the bottom end to the two support arms by the pivot extending therethrough. The pivot defining a single pivot axis about which the shaft is pivotable relative to the base plate between a first position in contact with only one of the retaining members and a second position in contact with only the other of the retaining members, for impact energy absorption.
    Type: Application
    Filed: June 7, 2011
    Publication date: February 16, 2012
    Inventor: ALAIN FOURNIER
  • Patent number: 7833521
    Abstract: Biologically active polypeptides comprising a therapeutically active polypeptide fused to human serum albumin or a variant of human serum albumin, methods for preparation, nucleotide sequences encoding such fusion polypeptides, expression cassettes comprising such nucleotide sequences, self-replicating plasmids containing such expression cassettes, and pharmaceutical compositions containing fusion polypeptides.
    Type: Grant
    Filed: October 29, 2007
    Date of Patent: November 16, 2010
    Assignee: Novozymes Biopharma DK A/S
    Inventors: Reinhard Fleer, Alain Fournier, Jean-Dominique Guitton, Gérard Jung, Patrice Yeh
  • Patent number: 7681833
    Abstract: A turboprop engine includes a power jet mounted coaxially to the engine axis (X-X?), and has a fan case and a gas ejecting system provided with two afterbody half-cowlings (10b) each of which is pivotable around an axis (A2) between open and closed positions, wherein the half-cowlings are connected to the downstream of the fan case through a ‘V-blade/V-groove’ system. In a first embodiment, the pivot axes (A2) make an angle ?>3° to the engine axis (X, X?) and a joint plane (Z2-Z2) between the afterbody half-cowlings and the downstream of the fan case makes to the plane (Y, Y?) perpendicular to the engine axis (X, X?) an angle ? in such a way that the difference between the angle ? and the angle ? is less than or equal to 3°. In the other embodiment, the axes are converged to each other in a downstream direction.
    Type: Grant
    Filed: April 19, 2005
    Date of Patent: March 23, 2010
    Assignee: Aircelle
    Inventors: Alain Fournier, Bernard Laboure, Robert Standish
  • Publication number: 20090328231
    Abstract: The invention concerns a method for protecting the data of an application compiled in intermediate for execution executed on a digital apparatus equipped with a virtual machine managing the execution of the code via a execution stack defining at least one stack frame corresponding to a method called during the execution of the code. A secured execution mode of the code involves the determination of at least one global checksum associated with each stack frame and, each time that a datum of the code is manipulated, the calculation of a local checksum associated with that datum. The calculation is on one hand, on the global checksum associated with the stack frame corresponding to the manipulated datum and, on the other hand, on at least one part of the other data constituting the stack frame.
    Type: Application
    Filed: July 18, 2007
    Publication date: December 31, 2009
    Applicant: GEMALTO SA
    Inventors: Benoit Gonzalvo, Jacques Jean-Alain Fournier
  • Publication number: 20090176276
    Abstract: Biologically active polypeptides comprising a therapeutically active polypeptide fused to human serum albumin or a variant thereof, methods for the preparation thereof, nucleotide sequences encoding such fusion polypeptides, expression cassettes comprising such nucleotide sequences, self-replicating plasmids containing such expression cassettes, and pharmaceutical compositions containing said fusion polypeptides.
    Type: Application
    Filed: October 29, 2007
    Publication date: July 9, 2009
    Inventors: Reinhard Fleer, Alain Fournier, Jean-Dominique Guitton, Gerard Jung, Patrice Yeh
  • Publication number: 20090028790
    Abstract: The present invention relates to an adrenomedullin derivative including an adrenomedullin peptide, or a fragment thereof chelated or otherwise bound to at least one active agent. Examples of active agents include a paramagnetic element, a radioactive element and a fibrinolytic agent, among others. Paramagnetic agents have a distribution that is relatively easily shown through Magnetic Resonance Imaging (MRI). Radioactive agents have applications in imaging and delivery of radiations, depending on the specific element included in the active agent. Delivery of fibrinolytic agents mainly to a specific organ, such as for example to the lungs, allows to substantially improve the specificity and efficacy of thrombolytic therapy by allowing local delivery of the fibrinolytic agent, thereby reducing the risks of major bleeding in the therapy of the organ. If the organ is the lungs, a non-limiting example of pathology treatable with the fibrinolytic agent is pulmonary embolus.
    Type: Application
    Filed: May 12, 2008
    Publication date: January 29, 2009
    Inventors: Jocelyn Dupuis, Alain Fournier
  • Publication number: 20090005253
    Abstract: The invention relates to a novel double hybrid system and to the uses thereof. This system provides, in particular, a tool that enables the detection of the interruption of a protein-protein interaction. The developed system uses transcription interference as a mechanism for detecting a breaking up of interacting protein pairs. The developed double hybrid system can be applied to the screening of molecules enabling the detection of molecules breaking up a protein-protein interaction as well as enabling the identification of alleles lacking in the interaction of proteins involved in the protein-protein interactions.
    Type: Application
    Filed: October 24, 2005
    Publication date: January 1, 2009
    Applicant: AVENTIS PHARMA S.A.
    Inventors: Alain Fournier, Ralf Behrens, Silvio Bandiera
  • Publication number: 20080274050
    Abstract: The present invention relates to an adrenomedullin derivative including an adrenomedullin peptide chelated with at least one active agent. Examples of active agents include a paramagnetic element, a radioactive element and a fibrinolytic agent, among others. Paramagnetic agents have a distribution that is relatively easily shown through Magnetic Resonance Imaging (MRI). Radioactive agents have applications in imaging and delivery of radiations, depending on the specific element included in the active agent. Delivery of fibrinolytic agents mainly to a specific organ, such us for example to the lungs, allows to substantially improve the specificity and efficacy of thrombolytic therapy by allowing local delivery of the fibrinolytic agent, thereby reducing the risks of major bleeding in the therapy of the organ. If the organ is the lungs, a non-limiting example of pathology treatable with the fibrinolytic is pulmonary embolus.
    Type: Application
    Filed: May 24, 2005
    Publication date: November 6, 2008
    Applicant: INSTITUT DE CARDIOLOGIE DE MONTRÉAL
    Inventors: Jocelyn Dupuis, Alain Fournier
  • Patent number: RE40940
    Abstract: The present invention concerns DNA sequences from the K. lactis PGK gene having transcriptional promoter activity. to expression vectors comprising these sequences and to their use for the production of proteins.
    Type: Grant
    Filed: February 23, 2001
    Date of Patent: October 20, 2009
    Assignee: Aventis Pharma S.A.
    Inventors: Reinhard Fleer, Alain Fournier, Jean-Francois Mayaux, Patrice Yeh